SCHEMBL3556217

SCHEMBL3556217

COC(=O)c1cc(Br)cc(-c2ccccn2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.51
GRM5 P41594 2/20 0.49
TSHR P16473 2/20 0.47
POLB P06746 2/20 0.47
GAA P10253 1/20 0.47
KAT6A Q92794 2/20 0.46
TGFBR1 P36897 1/20 0.46
KDM4E B2RXH2 5/20 0.44
KDM6B O15054 1/20 0.44
KDM5C P41229 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
KDM2A Q9Y2K7 1/20 0.44
KDM3A Q9Y4C1 1/20 0.44
NOTUM Q6P988 1/20 0.44
MAPT P10636 1/20 0.44
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
ERN1 O75460 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL989567 0.90 AXL (0.56) AXLGRM5TSHRPOLBGAA
SCHEMBL475480 0.90 AXL (0.56) AXLGRM5TSHRPOLBGAA
SCHEMBL16107415 0.84 KDM4E (0.60) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL5562975 0.84 GRM5 (0.64) AXLGRM5TSHRKAT6ATGFBR1
SCHEMBL4542026 0.83 AXL (0.51) AXLGRM5TSHRPOLBKAT6A
SCHEMBL11998005 0.81 AXL (0.49) AXLGRM5TSHRPOLBKAT6A
SCHEMBL3554650 0.81 AXL (0.52) AXLGRM5TSHRPOLBKAT6A
SCHEMBL16139806 0.81 KDM4E (0.46) TGFBR1KDM4EKDM6BKDM5CKDM4C
SCHEMBL311095 0.80 NOTUM (0.43) POLBNOTUMMAPTNPC1
SCHEMBL30772298 0.79 TGFBR1 (0.60) AXLTSHRPOLBTGFBR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963312-B1 BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC (US) 2014-07-02 EP disclosed
US-7838676-B2 Beta-secretase modulators and methods of use AMGEN INC. (US) 2010-11-23 US disclosed
EP-1963312-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2008-09-03 EP disclosed
US-20070173521-A1 Beta-secretase modulators and methods of use AMGEN INC. 2007-07-26 US disclosed
WO-2007061930-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173521-A1 Beta-secretase modulators and methods of use BACE1, BACE2, APP AXL 3013/4885GRM5 1069/4885TSHR 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.